Abstract
Immortal cell lines are used to investigate various aspects of neurodegeneration. These cells display high glycolytic turnover rate and produce an abundant amounts of lactate. Our previous studies indicate that these cells survive the loss of mitochondrial oxidative phosphorylation (OXPHOS) with ample glucose supply. In the current study, we investigate if cell type (w/variation in basal metabolic rate (MR)), can alter glucose utilization patterns which in turn may affect LC50 for the mitochondrial toxin 1-methyl-4-phenylpyridinium (MPP+) in various cell lines. The data obtained indicate that cell lines MRs examined were generally consistent with the average of species adult body weight where mouse N-2A > rat-PC-12 > human SH-SY5Y. A higher MR was associated with accelerated utilization of glucose and earlier cell death with MPP+: LC50 mouse = 294 µM, rat = 695 µM, and human = 5.25 mM at 24 h. Cell death appears to be a function of the velocity by which glucose disappears, leading to the failure of glycolysis and subsequent halt of energy production. Similar effects were also observed at higher plating densities where the demand for glucose is amplified. A time-lapse study of MPP+ toxicity (0–36 h) in N-2A cells indicates that an anaerobic shift occurs as early as 2 h (evidenced by a rise in lactate), followed by a descent in glucose concentrations at 4 h and exhaustion of glucose supplies at 22 h which was associated with the first detectable sign of cell death. It was also noted that MPP+ toxicity was not associated with the generation of reactive oxygen species (O −2 , H202, and NO2) and was not attenuated by adding catalase or superoxide dismutase to the media. On the other hand, MPP+ toxicity was reversed by providing additional supply of glucose, pyruvate ± mitochondrial monocarboxylate transporter blocker (α-cyano-4-HCA), or pyruvate ± pyruvate dehydrogenase inhibitor (octanoyl-CoA), suggesting that the exclusive anaerobic survival compensates for the loss of OXPHOS by MPP+. To examine if neuroblastoma were capable of surviving the deprivation of O2 for 24 h, a range of hypoxia to anoxia was established with various concentrations of dithionite. The data suggest that cell lines examined continue to thrive when incubated with high-glucose media (25 mM). In summary, vulnerability of immortal neuroblastoma cell lines to MPP+ toxicity is dependent upon glucose concentrations within the media and cell MR, which indirectly dominates the velocity of glucose use and its end point disappearance, leading to cell death by ergogenic failure.
Similar content being viewed by others
References
Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy. 2007;53:233–56.
Alvira D, Yeste-Velasco M, Folch J, Verdaguer E, Canudas AM, Pallàs M, et al. Comparative analysis of the effects of resveratrol in two apoptotic models: inhibition of complex I and potassium deprivation in cerebellar neurons. Neuroscience. 2007;147:746–56.
Amazzal L, Lapôtre A, Quignon F, Bagrel D. Mangiferin protects against 1-methyl-4-phenylpyridinium toxicity mediated by oxidative stress in N2A cells. Neurosci Lett. 2007;418:159–64.
Basma AN, Heikkila RE, Saporito MS, Philbert M, Geller HM, Nicklas WJ. 1-Methyl-4-(2′-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced toxicity in PC12 cells is enhanced by preventing glycolysis. J Neurochem. 1992;58:1052–9.
Bournival J, Quessy P, Martinoli MG. Protective effects of resveratrol and quercetin against MPP(+)-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol Neurobiol. 2009;29:1169–80.
Burstein DE, Reder I, Weiser K, Tong T, Pritsker A, Haber RS. GLUT1 glucose transporter: a highly sensitive marker of malignancy in body cavity effusions. Mod Pathol. 1998;11:392–6.
Caneda-Ferrón B, De Girolamo LA, Costa T, Beck KE, Layfield R, Billett EE. Assessment of the direct and indirect effects of MPP+ and dopamine on the human proteasome: implications for Parkinson’s disease aetiology. J Neurochem. 2008;105:225–38.
Cheung YT, Lau WK, Yu MS, Lai CS, Yeung SC, So KF, et al. Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology. 2009;30:127–35.
Chinta SJ, Rane A, Yadava N, Andersen JK, Nicholls DG, Polster BM. Reactive oxygen species regulation by AIF- and complex I-depleted brain mitochondria. Free Radic Biol Med. 2009;46:939–47.
Cosi C, Marien M. Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): prevention by the poly (ADP-ribose) polymerase inhibitor, benzamide. Brain Res. 1998;809:58–67.
Cosi C, Marien M. Implication of poly (ADP-ribose) polymerase (PARP) in neurodegeneration and brain energy metabolism. Decreases in mouse brain NAD+ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide. Ann N Y Acad Sci. 1999;890:227–39.
Evans SM, Casartelli A, Herreros E, Minnick DT, Day C, George E, et al. Development of a high throughput in vitro toxicity screen predictive of high acute in vivo toxic potential. Toxicol In Vitro. 2001;15:579–84.
Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res. 2003;63:3847–54.
Godinot C, de Laplanche E, Hervouet E, Simonnet H. Actuality of Warburg’s views in our understanding of renal cancer metabolism. J Bioenerg Biomembr. 2007;39:235–41.
Griffiths JR, McIntyre DJ, Howe FA, Stubbs M. Why are cancers acidic? A carrier-mediated diffusion model for H+ transport in the interstitial fluid. Novartis Found Symp. 2001;240:46–62.
Han YS, Lee CS. Antidepressants reveal differential effect against 1-methyl-4-phenylpyridinium toxicity in differentiated PC12 cells. Eur J Pharmacol. 2009;604:36–44.
Hashimoto T, Nishi K, Nagasao J, Tsuji S, Oyanagi K. Magnesium exerts both preventive and ameliorating effects in an in vitro rat Parkinson disease model involving 1-methyl-4-phenylpyridinium (MPP+) toxicity in dopaminergic neurons. Brain Res. 2008;1197:143–51.
Hennipman A, van Oirschot BA, Smits J, Rijksen G, Staal GE. Glycolytic enzyme activities in breast cancer metastases. Tumour Biol. 1988;9:241–8.
Holt A, Sharman DF, Baker GB, Palcic MM. A continuous spectrophotometric assay for monoamine oxidase and related enzymes in tissue homogenates. Anal Biochem. 1997;244:384–92.
Ikezaki K, Black KL, Conklin SG, Becker DP. Histochemical evaluation of energy metabolism in rat glioma. Neurol Res. 1992;14:289–93.
Iwashita A, Yamazaki S, Mihara K, Hattori K, Yamamoto H, Ishida J, et al. Neuroprotective effects of a novel poly (ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. J. J Pharmacol Exp Ther. 2004;309:1067–78.
Jia H, Li X, Gao H, Feng Z, Li X, Zhao L, et al. High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson’s disease. J Neurosci Res. 2008;86:2083–90.
Jung M, Jin G, Kim S, Kim Y, Park Y. Neuroprotective effect of methanol extract of Phellodendri Cortex against 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis in PC-12 cells. Cell Biol Int. 2009;33:957–63.
Koga K, Mori A, Ohashi S, Kurihara N, Kitagawa H, Ishikawa M, Mitsumoto Y, Nakai M. H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice. Eur J Neurosci. 2006;23:1077–81.
Koukourakis MI, Pitiakoudis M, Giatromanolaki A, Tsarouha A, Polychronidis A, Sivridis E, et al. Oxygen and glucose consumption in gastrointestinal adenocarcinomas: correlation with markers of hypoxia, acidity and anaerobic glycolysis. Cancer Sci. 2006;97:1056–60.
Liu H, Savaraj N, Priebe W, Lampidis TJ. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (model C). Biochem Pharmacol. 2002;64:745–51.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–75.
Maruoka N, Murata T, Omata N, Takashima Y, Fujibayashi Y, Wada Y. Topological and chronological features of the impairment of glucose metabolism induced by 1-methyl-4-phenylpyridinium ion (MPP(+)) in rat brain slices. J Neural Transm. 2007;114:1155–9.
Maublant J, Vuillez JP, Talbot JN, Lumbroso J, Muratet JP, Herry JY, et al. Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology. Bull Cancer. 1998;85:935–50.
Mazzio E, Soliman KF. D-(+)-glucose rescue against 1-methyl-4-phenylpyridinium toxicity through anaerobic glycolysis in neuroblastoma cells. Brain Res. 2003a;962:48–60.
Mazzio E, Soliman KF. The role of glycolysis and gluconeogenesis in the cytoprotection of neuroblastoma cells against 1-methyl 4-phenylpyridinium ion toxicity. Neurotoxicology. 2003b;24:137–47.
Mazzio EA, Reams RR, Soliman KF. The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro. Brain Res. 2004;1004:29–44.
Mukherjee SK, Klaidman LK, Yasharel R, Adams Jr JD. Increased brain NAD prevents neuronal apoptosis in vivo. Eur J Pharmacol. 1997;330:27–34.
Palacios JM, Wiederhold KH. Acute administration of 1-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a compound producing parkinsonism in humans, stimulates [2-14C]deoxyglucose uptake in the regions of the catecholaminergic cell bodies in the rat and guinea pig brains. Brain Res. 1984;301:187–91.
Palombo E, Porrino LJ, Bankiewicz KS, Crane AM, Kopin IJ, Sokoloff L. Administration of MPTP acutely increases glucose utilization in the substantia nigra of primates. Brain Res. 1988;453:227–34.
Pan JG, Mak TW. Metabolic targeting as an anticancer strategy: dawn of a new era? Sci STKE. 2007;381:Pe14.
Park SK, Murphy S. Duration of expression of inducible nitric oxide synthase in glial cells. J Neurosci Res. 1994;39:405–11.
Pizarro J, Junyent F, Verdaguer E, Jordan J, Beas-Zarate C, Pallàs M, Camins A, Folch J. Effects of MPP(+) on the molecular pathways involved in cell cycle control in B65 neuroblastoma cells. Pharmacol Res. 2010;61:391–99.
Pu X, Song Z, Li Y, Tu P, Li H. Acteoside from Cistanche salsa inhibits apoptosis by 1-methyl-4-phenylpyridinium ion in cerebellar granule neurons. Planta Med. 2003;69:65–6.
Sadava D, Orians GH, Heller CH. Life: the science of biology: volume III: plants and animals. 7th ed. New York: Freeman; 2003. p. 866.
Schulz JB, Henshaw DR, Matthews RT, Beal MF. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol. 1995;132:279–83.
Schwartzman RJ, Alexander GM. Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson’s disease. Brain Res. 1985;358:137–43.
Schwartzman RJ, Alexander GM, Ferraro TN, Grothusen JR, Stahl SM. Cerebral metabolism of parkinsonian primates 21 days after MPTP. Exp Neurol. 1998;102:307–13.
Seyfried J, Soldner F, Kunz WS, Schulz JB, Klockgether T, Kovar KA, et al. Effect of 1-methyl-4-phenylpyridinium on glutathione in rat pheochromocytoma PC 12 cells. Neurochem Int. 2000;36:489–97.
Sullivan R, Paré GC, Frederiksen LJ, Semenza GL, Graham CH. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther. 2008;7:1961–73.
Sun W, Zhou S, Chang SS, McFate T, Verma A, Califano JA. Mitochondrial mutations contribute to HIF1alpha accumulation via increased reactive oxygen species and up-regulated pyruvate dehydrogenease kinase 2 in head and neck squamous cell carcinoma. Clin Cancer Res. 2009;15:476–84.
Tang X, Li Y, Zhao J, Shen X, Yang C, Fan L, Hu B, Li Y, Liao D. Neuroprotective effect of asymmetrical dimethylarginine against 1-methyl-4-phenylpyridinium ion-induced damage in PC12 cells. Clin Exp Pharmacol Physiol. 2010 (in press).
Tatton WG, Chalmers-Redman RM, Rideout HJ, Tatton NA. Mitochondrial permeability in neuronal death: possible relevance to the pathogenesis of Parkinson’s disease. Parkinsonism Relat Disord. 1999;5:221–9.
Tian YY, Jiang B, An LJ, Bao YM. Neuroprotective effect of catalpol against MPP(+)-induced oxidative stress in mesencephalic neurons. Eur J Pharmacol. 2007;568:142–8.
Tóth J. The effect of oxygenation on the biological behaviour of tumours. Orv Hetil. 2007;148:1415–20.
Tsai SJ, Yin MC. Antioxidative and anti-inflammatory protection of oleanolic acid and ursolic acid in PC12 cells. J Food Sci. 2008;73:H174–8.
Wang YM, Pu P, Le WD. ATP depletion is the major cause of MPP+ induced dopamine neuronal death and worm lethality in alpha-synuclein transgenic C. elegans. Neurosci Bull. 2007;23:29–35.
Williams AC, Cartwright LS, Ramsden DB. Parkinson’s disease: the first common neurological disease due to auto-intoxication? QJM: Int J Med. 2005;98:215–26.
Wruck CJ, Claussen M, Fuhrmann G, Römer L, Schulz A, Pufe T, et al. Luteolin protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway. J Neural Transm Suppl. 2007;72:57–67.
Acknowledgment
This research work was supported by a grant from NIH NCRR RCMI program (G12RR 03020). Dr. Y. Soliman was supported by a faculty development grant from the RCMI program of Universidad Central del Caribe, Bayamon, PR, NIH Grant NCRR RCMI grant (G12 RR 03035).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mazzio, E.A., Soliman, Y.I. & Soliman, K.F.A. Variable toxicological response to the loss of OXPHOS through 1-methyl-4-phenylpyridinium-induced mitochondrial damage and anoxia in diverse neural immortal cell lines. Cell Biol Toxicol 26, 527–539 (2010). https://doi.org/10.1007/s10565-010-9161-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10565-010-9161-7